Lantern Pharma
LTRN
12 hedge funds and large institutions have $3.02M invested in Lantern Pharma in 2020 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 1 closing their positions.
700% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 1
140% more funds holding
Funds holding: 5 → 12 (+7)
95% more capital invested
Capital invested by funds: $1.55M → $3.02M (+$1.47M)
0.61% more ownership
Funds ownership: 1.96% → 2.57% (+0.61%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VC
Voss Capital
Houston,
Texas
|
+$508K |
| 2 |
Morgan Stanley
New York
|
+$309K |
| 3 |
RCG
Rock Creek Group
Washington,
District of Columbia
|
+$164K |
| 4 |
BlackRock
New York
|
+$72.5K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$14.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ZCA
Zeke Capital Advisors
Berwyn,
Pennsylvania
|
-$507K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$20.6K |
| 3 |
TI
tru Independence
Portland,
Oregon
|
-$6 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
ZCA
1
Zeke Capital Advisors
Berwyn,
Pennsylvania
| $1.6M | -$507K | -35,000 | -29% |
|
|
VC
2
Voss Capital
Houston,
Texas
| $661K | +$508K | +35,067 | New |
|
|
3
Morgan Stanley
New York
| $403K | +$309K | +21,384 | New |
|
|
RCG
4
Rock Creek Group
Washington,
District of Columbia
| $213K | +$164K | +11,306 | New |
|
|
5
BlackRock
New York
| $94K | +$72.5K | +5,009 | New |
|
|
6
Royal Bank of Canada
Toronto,
Ontario, Canada
| $19K | +$14.5K | +1,000 | New |
|
|
TRCT
7
Tower Research Capital (TRC)
New York
| $13K | +$7.8K | +539 | +317% |
|
|
CCM
8
Chiron Capital Management
Tallahassee,
Florida
| $9K | +$7.24K | +500 | New |
|
9
US Bancorp
Minneapolis,
Minnesota
| $4K | – | – | – |
|
|
10
UBS Group
Zurich,
Switzerland
| $2K | -$20.6K | -1,421 | -93% |
|
|
FCA
11
FinTrust Capital Advisors
Greenville,
South Carolina
| $2 | +$1.3K | +90 | New |
|
|
TI
12
tru Independence
Portland,
Oregon
| – | -$6 | -500 | Closed |
|
13
Wells Fargo
San Francisco,
California
| – | +$159 | +11 | New |
|
LTRN Hedge Fund Activity: Q3 2020 in Review
12 of the 4,957 institutional investors tracked by Wall St. Rank reported a position in Lantern Pharma (LTRN) for Q3 2020, worth a combined $3.02M — up 95% from $1.55M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new LTRN positions and 1 closed out — a net gain of 7 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Voss Capital, opening a new position worth an estimated $508K. The largest seller was Zeke Capital Advisors, cutting an estimated $507K.
- 12 institutional investors held Lantern Pharma (LTRN) as of Q3 2020, up from 5 in Q2 2020.
- Funds reported $3.02M of Lantern Pharma stock for Q3 2020, up 95% quarter-over-quarter.
- 8 funds opened new Lantern Pharma positions in Q3 2020 and 1 closed out, a net change of +7 holders.
- The largest Lantern Pharma buyer in Q3 2020 was Voss Capital, an estimated $508K added.
- The largest Lantern Pharma seller in Q3 2020 was Zeke Capital Advisors, an estimated $507K sold.
Based on aggregated 13F filings for Q3 2020.